# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Risk sentiment deteriorated sharply on Wednesday as a wave of disappointing earnings guidance and escalating U.S.-China trade t...
BTIG analyst Marie Thibault reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $132 price target.
Goldman Sachs analyst David Roman reiterated a Buy rating and $120 price target for Boston Scientific after strong Q3 results a...
Boston Scientific Q3 revenue hit $5.07 billion, beating forecasts. The company raised its full-year guidance based on strong se...